BAX-826

N/A

Report date: 2023/04/25 15:33:16

Base Information

Drug NameBAX-826
Drug Alias NamePSA-FVIII - Shire/Xenetic BiosciencesPolysialylated rFVIIIPSA-rFVIIIBax-826BA-826 +[8] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaPolandNetherlands +[9] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaxalta Incorporated
Active IndicationsN/A
Inactive IndicationsHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A